Cardiovascular Diseases Epidemiology Study

Global Cardiovascular Diseases Epidemiology Study

Cardiovascular Diseases Study Objective:

To determine the prevalence and incidence of cardiovascular diseases among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of cardiovascular diseases within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Cardiovascular Diseases Study USP:

• 
  

  This epidemiological study on cardiovascular diseases stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

  
  


• 
  

  By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of cardiovascular diseases related health problems.

  
  


• 
  

  Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of cardiovascular diseases but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing cardiovascular diseases cases.

  
  

Cardiovascular Diseases related Study Overview:

The study defines cardiovascular diseases as an advanced form of disease. The significance of studying cardiovascular diseases epidemiology is due to its increasing prevalence in different age populations.

Cardiovascular Diseases Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying cardiovascular diseases cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Cardiovascular Diseases Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between cardiovascular diseases and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Cardiovascular Diseases study summary:

Cardiovascular Diseases study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the cardiovascular diseases worldwide.

Cardiovascular Diseases Disease overview:

Cardiovascular diseases refer to group of disorders of the heart and blood vessels, often caused by narrowing or blocking of blood vessels. It shows wide range of conditions that affect the heart’s ability to function properly.

Types of cardiovascular disease include coronary artery disease, heart failure, stroke, peripheral artery disease, arrhythmias, valvular heart disease, congenital heart defects, hypertension.

According to world health organisation (WHO), cardiovascular diseases (CVDs) is one of the leading causes of death worldwide. It is estimated that in 2019, 17.9 million people died due to CVDs which represents global deaths of 32% among all the deaths, of which 85% were due to heart attack and stroke. low- and middle-income countries are seen with Over three quarters of CVD deaths. In the United States, with every 40 seconds someone has a heart attack. in the United States, every year, about 805,000 people have a heart attack.

There are various therapeutics and medical devices available in the market for the treatment of these diseases, the Key market players manufacturing therapeutics for the treatment of cardiovascular diseases include, Daiichi Sankyo, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Bayer AG, Merck Co, Sanofi Aventis, Boehringer Ingelheim, Takeda Pharmaceutical, Abbot, Novartis, Johnson Johnson, AstraZeneca Plc.

February 2025, Kestra Medical Technologies, a medtech company based in Washington, is set to go public on the Nasdaq Global Select Market under the ticker symbol KMTS. The company is recognised for its wearable heart monitors and defibrillators, specially its Assure wearable cardioverter defibrillator (WCD). This vest-like device is developed for protecting patients from sudden cardiac arrest. WCDs have been used for over 20 years to protect patients with high risk of sudden cardiac arrest, the market was previously limited to a single solution until the Assure WCD received FDA approval in July 2021. In July 2024, Kestra successfully raised $196 million from various investors.

October 2022 The United States FDA has given Medtronic plc permission for extended Labeling of a cardiac lead that uses the heart's natural electrical circuitry to deliver essential therapy while avoiding problems like cardiomyopathy frequently associated with conventional pacing techniques.

Cardiovascular Diseases Demographic and Environmental Risk Factors:

Age and Sex: One in every 20 adults with age of 20 years and more have cardiovascular disease, in 2022 1 death in every 5 deaths is due to cardiovascular diseases and among the adults at younger age with less than 65 years. Globally higher age standardised Cardiovascular Death rate with about 280.8 deaths per 100,000 people in year 2019 was seen in males, compared to females with 240 deaths per 100,000 people in year 2019. CVD death rates were seen to be higher in males than females across all countries with high income regions, central Europe, Eastern Europe, and Central Asia region, and South Asia region.

Ethnicity: Heart disease is one of leading cause of death in most racial and ethnic groups in US, these include African American, American Indian, Alaska Native, Hispanic, White men. And for women Pacific Islands and Asian American, American Indian, Alaska Native, and Hispanic women, heart disease is second cause of death. percentages of all deaths caused by heart disease in 2021, in American Indian or Alaska Native was 15.5%, for Asian 18.6 %, Black (Non-Hispanic) were seen with 22.6 %, Native Hawaiian or Other Pacific Islander were having 18.3 %, White (Non-Hispanic) with 18.0 % and Hispanic with11.9 %, for All racial and ethnic groups the average death rate in 2021 was 17.4%.

Risk Factors causing cardiovascular diseases: Cardiovascular disease is caused due to combination of socio economic, metabolic behavioural, and environmental risk factors which includes high blood pressure, unhealthy diet, high cholesterol, diabetes, air pollution, obesity, tobacco use, kidney disease, physical inactivity, harmful use of alcohol and stress.

Behavioural factors include no sufficient physical activity, high levels of sodium intake, higher alcohol consumption, and tobacco smoking. Metabolic factors include high blood pressure, high fasting plasma glucose, high body-mass index, high levels of low-density lipoprotein (LDL) cholesterol, and diabetes.

Environmental factors, like ambient air pollution can also cause this disease. In 2021, according to the Global Burden of Disease Study, high blood pressure was the leading modifiable risk factor globally for mortality and contributed to 10.8 million CVD deaths worldwide.

Cardiovascular Diseases Market Scope:

Drivers: The increasing incidence and prevalence of cardiovascular diseases (CVDs) -are driven by several factors, including an aging population, rising obesity and diabetes rates, and unhealthy lifestyle choices. According to the World Health Organization (WHO), in 2022, 1 in every 8 people globally was living with obesity, with adult obesity rates doubling since 1990 and adolescent obesity rates quadrupling worldwide. Additionally, around 830 million people worldwide are living with diabetes. This surge in obesity and diabetes significantly contributes to the rise in CVDs, as both conditions are major risk factors for cardiovascular diseases. With more people suffering from CVDs due to these interconnected factors, the demand for cardiovascular drugs is expected to increase, highlighting the urgent need for effective prevention and treatment strategies.

Growing Demand for Novel Therapies-The Cardiovascular Drugs Market is witnessing a growing demand for novel therapies. This is due to the increasing prevalence of chronic diseases, such as heart failure and hypertension, where patients require treatment for prolonged periods. Moreover, the rising cost of healthcare is driving the demand for more cost-effective therapies.

Technological Advancements- Technological advancements are also playing a key role in the growth of the Cardiovascular Drugs Market. The development of new drug delivery systems, such as nanotechnology and gene therapy, is improving the efficacy and safety of cardiovascular drugs. For instance, in January 2024, Medtronic pulsed-field ablation (PFA) for atrial fibrillation was approved by FDA, placing them firmly at the forefront of the PFA segment. This advanced treatment is less invasive for patients suffering from arrhythmia (irregular heart rhythms).

Restraints: High treatment cost. Side effects of long-term medications, lack of awareness in low-income countries, regulatory and reimbursement issues are some of the factors which can hamper the growth of the cardiovascular disease medicines market.